文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

解析滤泡性淋巴瘤的复杂性:见解与创新

Unraveling the complexity of follicular lymphoma: insights and innovations.

作者信息

Li Xijing, Li Nannan, Liu Yinghui, An Licai

机构信息

Department of Pathology, Yantaishan Hospital Yantai 264003, Shandong, China.

Department of Hematology, Yantai Yuhuangding Hospital Yantai 264001, Shandong, China.

出版信息

Am J Cancer Res. 2024 Dec 15;14(12):5573-5597. doi: 10.62347/MFUG2190. eCollection 2024.


DOI:10.62347/MFUG2190
PMID:39803651
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11711519/
Abstract

This review discusses multiple aspects of follicular lymphoma (FL), including etiology, treatment challenges, and future perspectives. First, we delve into the etiology of FL, which involves a variety of pathogenic mechanisms such as gene mutations, chromosomal abnormalities, immune escape, immune system dysregulation, familial inheritance, and environmental factors. These mechanisms provide the context for understanding the diversity and complexity of FL. Second, we discuss the challenges faced when treating FL, particularly treatment resistance. Therapeutic resistance is a common problem in treatment, but by delving into the mechanisms of resistance, scientists have looked for strategies to combat it, including developing new drugs, improving treatments, and exploring combination therapy strategies. We also emphasize the breakthroughs in molecular biology, especially the study of targeting the BCL2 gene, which provides a new direction for targeted therapy in FL. Immunotherapy, small molecule targeted drugs, and individualized treatment strategies are also promising for the future treatment of FL. Finally, we look to the future, including research on therapeutic resistance, in-depth studies of genetics and gene expression, applications of gene editing and precision medicine, and clinical trials of new treatments. These lines of research offer additional opportunities for treating FL, and despite the challenges, the future is promising. This literature review provides comprehensive and integrated information for the in-depth understanding of FL and relevant treatment approaches.

摘要

本综述讨论了滤泡性淋巴瘤(FL)的多个方面,包括病因、治疗挑战和未来展望。首先,我们深入探讨FL的病因,其涉及多种致病机制,如基因突变、染色体异常、免疫逃逸、免疫系统失调、家族遗传和环境因素。这些机制为理解FL的多样性和复杂性提供了背景。其次,我们讨论了治疗FL时面临的挑战,特别是治疗耐药性。治疗耐药是治疗中的常见问题,但通过深入研究耐药机制,科学家们已在寻找应对策略,包括开发新药、改进治疗方法以及探索联合治疗策略。我们还强调了分子生物学的突破,尤其是针对BCL2基因的研究,这为FL的靶向治疗提供了新方向。免疫疗法、小分子靶向药物和个体化治疗策略对FL的未来治疗也很有前景。最后,我们展望未来,包括对治疗耐药性的研究、对遗传学和基因表达的深入研究、基因编辑和精准医学的应用以及新治疗方法的临床试验。这些研究方向为治疗FL提供了更多机会,尽管存在挑战,但未来充满希望。这篇文献综述为深入了解FL及相关治疗方法提供了全面且综合的信息。

相似文献

[1]
Unraveling the complexity of follicular lymphoma: insights and innovations.

Am J Cancer Res. 2024-12-15

[2]
Follicular lymphoma: The long and winding road leading to your cure?

Blood Rev. 2023-1

[3]
Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma.

Leuk Res. 2024-7

[4]
New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.

Semin Oncol. 2018-10-23

[5]
Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas.

World J Gastroenterol. 2023-12-28

[6]
Advances in the multi-omics landscape of follicular lymphoma.

Int J Biol Sci. 2023

[7]
Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.

Blood. 2025-3-16

[8]
Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.

J Hematol Oncol. 2021-6-30

[9]
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives.

Eur J Haematol. 2025-5

[10]
Establishment and characterization of a novel 'double-hit' follicular lymphoma cell line, FL-SJC.

J Cell Mol Med. 2020-7

本文引用的文献

[1]
Interstitial pneumonia development after chemotherapy in B-cell non-hodgkin's lymphoma patients: clinical profiles and risk factors.

Am J Cancer Res. 2024-9-15

[2]
Diagnostic value of baseline 18 F-FDG PET/CT and peripheral blood inflammatory markers for aggressive lymphoma in non-Hodgkin's lymphoma.

Nucl Med Commun. 2025-1-1

[3]
Non-Hodgkin's lymphoma involving chronic difficult-to-heal wounds: A case report.

World J Clin Oncol. 2024-8-24

[4]
A Persistent Pulmonary Puzzle: Diagnosing Hodgkin Lymphoma in a Young Female With Chronic Respiratory Symptoms.

Cureus. 2024-7-28

[5]
Identification of genetic subtypes in follicular lymphoma.

Blood Cancer J. 2024-8-7

[6]
Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.

Transplant Cell Ther. 2024-9

[7]
Non-neoplastic B-cell predominant lymphoid proliferations at the organs exposed to external environment mimicking lymphoma: A potential diagnostic pitfall.

Int J Immunopathol Pharmacol. 2024

[8]
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.

Nat Med. 2024-8

[9]
Two recurrent types of ::5' breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the and class switch recombination processes, respectively.

Leuk Lymphoma. 2024-8

[10]
Follicular Lymphoma Presenting With Symptomatic Bone Involvement: A Clinicopathologic and Molecular Analysis of 16 Cases.

Mod Pathol. 2024-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索